Not recommended for analgesia in immediate post-operative period or in situations characterised by narrow therapeutic index or rapidly varying analgesic requirement. Caution in patients known to or suspected of having history of drug or alcohol abuse or serious mental illness. Physical dependence can result with chronic use. Withdrawal is generally mild, begins after 2 days and may last up to 2 weeks; symptoms include agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal disorders. Sevodyne may cause positive reaction to sports doping control tests. Increased absorption of buprenorphine may occur if patches exposed to external heat sources. Fever in febrile patients may result in increased absorption and thereby increased risk of opioid reactions. Use cautiously with other central nervous system depressants. Do not use during pregnancy, lactation or in women of childbearing potential who are not using effective contraception. Prolonged use of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome. Patients should be warned about effect on driving and, if experiencing dizziness, drowsiness or blurred vision, they should not drive or use machines for at least 24 hours after patch removed. Side effects: For the full list of side effects consult SmPC. ‘Very Common’ ‘Common’ and ‘Serious’ side effects are included in prescribing information. Very common (≥1/10) side effects: headache, dizziness, somnolence, constipation, nausea, vomiting, pruritus, erythema, application site reaction. Common (≥1/100 to <1/10) side effects: anorexia, confusion, depression, insomnia, nervousness, anxiety, tremor, dyspnoea, abdominal pain, diarrhoea, dyspepsia, dry mouth, rash, sweating, exanthema, muscular weakness, tiredness, asthenic conditions, peripheral oedema. Uncommon Serious (≥1/1000 to <1/100) side effects: hypersensitivity, circulatory collapse, drug withdrawal syndrome, urinary incontinence. Rare Serious (≥1/10000 to <1/1000) side effects: anaphylactic reaction, angina, respiratory depression, respiratory failure. Not Known Serious (unknown frequency) side effects: anaphylactoid reaction, seizures, neonatal drug withdrawal syndrome. MA number: PL 35533/0059-0061. Cost: £5.53 for 5µg/hr patch x4 pack; £9.93 for 10µg/hr patch x4 pack; and £18.09 for 20µg/hr patch x4 pack. MAH: Aspire Pharma Ltd, Unit 4, Rotherbrook Court, Bedford Road, Petersfield, Hampshire GU32 3QG. Legal category: POM. Date last reviewed: April 2020 Version number: 1010311145 v 6.0.